Brief: Eloxx Strengthens Its Commitment To Cystic Fibrosis Through Reallocating Resources

Eloxx Pharmaceuticals

26/02/2020 22:30

Feb 26 (Reuters) - Eloxx Pharmaceuticals Inc  ELOX.O :
    * ELOXX STRENGTHENS ITS COMMITMENT TO CYSTIC FIBROSIS
THROUGH
REALLOCATING RESOURCES
    * ELOXX PHARMACEUTICALS INC - REITERATE TOPLINE DATA FROM
PHASE 2
CYSTIC FIBROSIS CLINICAL TRIALS FOR ELX-02 EXPECTED IN H1 2020
    * ELOXX PHARMACEUTICALS INC - GREGORY WILLIAMS APPOINTED
CHIEF
EXECUTIVE OFFICER AND NEIL BELLOFF CHIEF OPERATING OFFICER
    * ELOXX PHARMACEUTICALS INC - HEADCOUNT REALIGNMENT TO
REDUCE
OPERATING EXPENSES AND SIGNIFICANTLY EXTEND FUNDING OF
OPERATIONS THROUGH END OF 2021
    * ELOXX PHARMACEUTICALS - EXPECTS TO REPORT TOPLINE DATA
FROM ITS
PHASE 2 CYSTIC FIBROSIS CLINICAL TRIAL PROGRAM FOR ELX-02 DURING
FIRST HALF OF 2020

Source text for Eikon:  ID:nGNX6KLqC3 
Further company coverage:  ELOX.O 

 ((Reuters.Briefs@thomsonreuters.com;))